Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Procter & Gamble Health's interest expense for the
three
months ended in Jun. 2026 was ₹ -1 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Jun. 2026 was ₹-6 Mil.
Procter & Gamble Health (BOM:500126) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Procter & Gamble Health Ltd has enough cash to cover all of its debt. Its financial situation is stable.
Procter & Gamble Health Interest Expense Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Procter & Gamble Health Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Procter & Gamble Health (BOM:500126) has a Interest Expense of ₹-6 Mil as of Jun. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Procter & Gamble Health and its competitors.
Is Procter & Gamble Health's Interest Expense too high?
Procter & Gamble Health's current Interest Expense is ₹-6 Mil. Overall, Procter & Gamble Health has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Procter & Gamble Health's Interest Expense compare to ZTS?
Procter & Gamble Health's Interest Expense of ₹-6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Procter & Gamble Health and its competitors. Procter & Gamble Health's current Interest Expense is ₹-6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Procter & Gamble Health stock overvalued right now?
Based on GuruFocus' analysis, Procter & Gamble Health (BOM:500126) is currently considered Fairly Valued. The stock's GF Value™ is ₹6,514.01, compared to a current price of ₹5,933.70 — trading 8.9% below its estimated fair value. The current Interest Expense is ₹-6 Mil. Procter & Gamble Health's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Procter & Gamble Health (BOM:500126), the current Interest Expense is ₹-6 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Procter & Gamble Health (BOM:500126) Overvalued in 2026?
Based on GuruFocus' analysis, Procter & Gamble Health stock appears to be undervalued.
The current stock price of ₹5,933.70 is trading 8.9% below its estimated GF Value™ of ₹6,514.01.
GuruFocus considers Procter & Gamble Health to be Fairly Valued.
Key valuation signals for BOM:500126:
Interest Expense: ₹-6 Mil
GF Value™: ₹6,514.01 vs. price of ₹5,933.70 (8.9% below fair value)
No single metric tells the full story. See the BOM:500126 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Procter & Gamble Health Ltd is an India based pharmaceutical company engaged in manufacturing and selling of healthcare products, viz., vitamins, minerals and supplements. Patients are end consumers of the products. The Company's distribution channels (direct & indirect), inter alia, include distributors, health care professionals, pharmacies and chemists. Cosome, Evion, Neurobion, Nasivion, Polybion, Livogen and Seven Seas are some of the brands of the company. The geographical segments include sales in India and exports.
72GF Score
Get the complete analysis for BOM:500126
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500126 has been successfully added to your 
